Coherus BioSciences, Inc. (CHRS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Coherus BioSciences is a commercial-stage biopharmaceutical company focused on immunotherapies. The quarter was defined by significant portfolio restructuring, including the divestiture of two major franchises (CIMERLI and YUSIMRY) and a strategic shift in debt financing. The company's core commercial products are UDENYCA (biosimilar to Neulasta) and LOQTORZI (PD-1 inhibitor for nasopharyngeal carcinoma).
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $64.98 million | $58.72 million | $142.04 million | $91.15 million |
| Net Income (Loss) | $(12.92) million | $(42.87) million | $89.95 million | $(118.60) million |
| Diluted EPS | $(0.11) | $(0.49) | $0.73 | $(1.42) |
| Gross Margin | 56% | 58% | 56% | 54% |
| Cash & Equivalents | $159.24 million | $72.92 million | As of June 30, 2024 | |
| Total Debt (Carrying Value) | $264.10 million | $473.37 million | As of June 30, 2024 |
Note: YTD 2024 Net Income includes a $177.7 million gain on sale transactions.
Material Changes vs. Prior Period
- Portfolio Divestitures: The company completed the sale of its CIMERLI ophthalmology franchise to Sandoz (March 2024) for $187.8 million in total consideration and the YUSIMRY immunology franchise to HKF (June 2024) for $40.0 million upfront cash plus assumption of $17.0 million in inventory commitments. These transactions generated a net gain of $177.7 million for the six months ended June 30, 2024.
- Debt Restructuring: Coherus fully repaid its $250 million 2027 Term Loans during Q2 2024. This resulted in a $12.6 million loss on debt extinguishment due to prepayment premiums and make-whole payments. Concurrently, the company entered a new $38.7 million 2029 Term Loan and a Revenue Purchase and Sale Agreement (selling rights to a percentage of UDENYCA and LOQTORZI sales) for $37.5 million.
- Revenue Composition: Revenue growth was driven by UDENYCA ($50.9M in Q2) and LOQTORZI ($3.8M in Q2), partially offset by the cessation of CIMERLI and YUSIMRY revenue streams following their sales. A $6.3 million upfront payment from Apotex for Canadian rights to LOQTORZI was recognized in Q2.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses decreased by $10.0 million in Q2 compared to Q2 2023, primarily due to lower headcount and the absence of non-recurring acquisition costs. However, this included a $6.8 million impairment charge related to the Novartis out-license asset.
Guidance, Outlook, and Risks
- Outlook: Management expects 2024 net revenue to be higher than 2023, driven by UDENYCA and LOQTORZI growth, despite the divestitures. Gross margins are expected to improve in 2024 due to the expiration of the Amgen royalty on UDENYCA (July 2024) and the removal of profit-sharing obligations for CIMERLI and YUSIMRY.
- Liquidity: As of June 30, 2024, the company held $159.2 million in cash and cash equivalents. Management believes this, combined with product sales and ATM offering capacity, is sufficient to fund operations for at least 12 months.
- Risks:
- Regulatory & Market Access: Continued pressure on pricing and reimbursement for biosimilars and immuno-oncology products.
- Development Risks: Uncertainty regarding the clinical success of pipeline candidates (casdozokitug, CHS-114, CHS-1000).
- Legal: Ongoing evaluation of a demand letter from Zinc Health Services regarding UDENYCA sales (accrual of $6.4 million established).
- Debt Covenants: The new 2029 Term Loan includes financial covenants requiring the maintenance of specific cash levels.
Investor Verification Checklist
- Debt Obligations: Verify the terms of the new 2029 Term Loan and the Revenue Purchase and Sale Agreement, specifically the "mid-single digit" percentage of sales being sold and the 2.25x repayment cap.
- Transition Services: Review the duration and financial impact of the Transition Services Agreements (TSA) with Sandoz and HKF, which extend through December 31, 2024.
- Inventory Commitments: Confirm the status of the $17.0 million inventory purchase commitments assumed by HKF for YUSIMRY and the potential liability if HKF defaults.
- Legal Accruals: Monitor the resolution of the Zinc Health Services claim and the adequacy of the $6.4 million accrual.
- Pipeline Progress: Track enrollment and data readouts for casdozokitug (HCC) and CHS-114 (solid tumors) to assess future revenue potential beyond the core portfolio.